Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in mCRPC with Bone Metastases
NCT05265988Phase 2Completed
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Objective Response Rate on Bone Metastases (WB-DW-MRI) at 6 months. Started Nov 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05265988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265988.